ArticlePloS one2009
Induction of long-term protective immune responses by influenza H5N1 virus-like particles.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Next-generation intranasal influenza vaccines: mechanisms, platforms, and translational progress.Frontiers in immunology · 2026Review
- A self-adjuvanted VLPs-based Covid-19 vaccine proven versatile, safe, and highly protective.Scientific reports · 2024Article
- Sublingual Vaccination with Live Influenza Virus Induces Better Protection Than Oral Immunization in Mice.Life (Basel, Switzerland) · 2022Article
- Neuraminidase in Virus-like Particles Contributes to the Protection against High Dose of Avian Influenza Virus Challenge Infection.Pathogens (Basel, Switzerland) · 2021Article
- A conserved multi-epitope-based vaccine designed by targeting hemagglutinin protein of highly pathogenic avian H5 influenza viruses.3 Biotech · 2020Article
- Article
- Influenza virus-like particles harboring H9N2 HA and NA proteins induce a protective immune response in chicken.Influenza and other respiratory viruses · 2017Article
- Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.Scientific reports · 2017Article
- Mucosal vaccine delivery: Current state and a pediatric perspective.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Biomedical applications of glycosylphosphatidylinositol-anchored proteins.Journal of lipid research · 2016Review
- Progress in developing virus-like particle influenza vaccines.Expert review of vaccines · 2016Review
- Advances in novel influenza vaccines: a patent review.Journal of microbiology (Seoul, Korea) · 2016Review
- Yeast Surface-Displayed H5N1 Avian Influenza Vaccines.Journal of immunology research · 2016Article
- Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like Particles.Frontiers in cellular and infection microbiology · 2016Article
- The application of virus-like particles as vaccines and biological vehicles.Applied microbiology and biotechnology · 2015Review
- Article
- Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses.Nanomedicine : nanotechnology, biology, and medicine · 2015Article
- Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity.Biotechnology and bioengineering · 2015Article
- Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems.BMC biotechnology · 2015Article
- Distinct B-cell populations contribute to vaccine antigen-specific antibody production in a transgenic mouse model.Immunology · 2014Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
backgroundRecurrent outbreaks of highly pathogenic H5N1 avian influenza virus pose a threat of eventually causing a pandemic. Early vaccination of the population would be the single most effective measure for the control of an emerging influenza pandemic. METHODOLOGY/PRINCIPAL
findingsInfluenza virus-like particles (VLPs) produced in insect cell-culture substrates do not depend on the availability of fertile eggs for vaccine manufacturing. We produced VLPs containing influenza A/Viet Nam1203/04 (H5N1) hemagglutinin, neuraminidase, and matrix proteins, and investigated their preclinical immunogenicity and protective efficacy. Mice immunized intranasally with H5N1 VLPs developed high levels of H5N1 specific antibodies and were 100% protected against a high dose of homologous H5N1 virus infection at 30 weeks after immunization. Protection is likely to be correlated with humoral and cellular immunologic memory at systemic and mucosal sites as evidenced by rapid anamnestic responses to re-stimulation with viral antigen in vivo and in vitro. CONCLUSIONS/SIGNIFICANCE: These results provide support for clinical evaluation of H5N1 VLP vaccination as a public health intervention to mitigate a possible pandemic of H5N1 influenza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.